ABBV-383 is a promising drug that works as a bi-specific antibody designed to bring the immune system to cancer cells, specifically plasma cells. It's currently being studied in a phase one trial and has shown effectiveness at a recommended dose of 60 milligrams. Watch the video below for more information on how it works, its side effects, dosing, and administration. You can watch the whole course at HealthTree University.
We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!
ABBV-383 is a promising drug that works as a bi-specific antibody designed to bring the immune system to cancer cells, specifically plasma cells. It's currently being studied in a phase one trial and has shown effectiveness at a recommended dose of 60 milligrams. Watch the video below for more information on how it works, its side effects, dosing, and administration. You can watch the whole course at HealthTree University.
We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!
about the author
Cynthia Chmielewski
Cynthia (Cindy) Chmielewski is a professional educator and myeloma advocate. As a former teacher, she now teaches myeloma patients how to advocate for themselves as the Director of HealthTree University. You can follow her on Twitter @myelomateacher
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.